Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] The company is in the pharma sector and has already created an extra facility for its product lines and has the necessary certifications in hand for global markets. Due to the pandemic and the thrust for expansion, it posted static top lines but managed to get higher margins for certain products. It is now ready with additional capacities to reap the benefits of demand. Considering fancy for pharma sector counters, investors may consider an investment with a medium to long-term perspective in this fully priced issue. Read detail review...
JFL Life Sciences IPO Reviews, analysis and views by popular members. Read JFL Life Sciences Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
RHP